BioSpace

ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak

After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, analysts are more keen on the personalized mRNA cancer vaccine data that last week spurred a stock selloff for both partners.

By BioSpace

1 min read
ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights